Previous 10 | Next 10 |
Gainers: NeuroMetrix NURO +233%.NeuroBo Pharmaceuticals NRBO +92%.Staffing 360 Solutions (STAF) +38%.LSB Industries (LXU) +36%.Femasys (FEMY) +27%.Ideal Power (IPWR) +26%.Endo International plc ENDP +25%.PainReform (PRFX) +21%.LifeVantage Corporation (LFVN) +16%.Immunome IMNM...
PainReform (PRFX): Q1 net loss of $2.04MCash and cash equivalents of $19.42MPress Release For further details see: PainReform reports Q1 results
HERZLIYA, Israel, May 13, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the first quarter ended Mar...
PainReform Ltd. (NASDAQ:PRFX) traded at a new 52-week low today of $3.16. So far today approximately 500,000 shares have been exchanged, as compared to an average 30-day volume of 136,000 shares. PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the re...
Shares of PainReform Ltd. (NASDAQ:PRFX) traded today at $3.09, breaking its 52-week low. Approximately 500,000 shares have changed hands today, as compared to an average 30-day volume of 136,000 shares. Potential upside of 40.2% exists for PainReform Ltd., based on a current level of $3....
PainReform Ltd. (NASDAQ:PRFX) traded at a new 52-week low today of $3.70. This new low was reached on above average trading volume as 500,000 shares traded hands, while the average 30-day volume is approximately 136,000 shares. PainReform Ltd. has overhead space with shares priced $3.89,...
Shares of PainReform Ltd. (NASDAQ:PRFX) traded today at $3.61, breaking its 52-week low. This new low was reached on above average trading volume as 500,000 shares traded hands, while the average 30-day volume is approximately 136,000 shares. In the past 52 weeks, shares of PainReform Lt...
Gainers: Clovis Oncology (CLVS) +43%, Marker Therapeutics (MRKR) +23%, Alector (ALEC) +17%, Aravive (ARAV) +14%, Ortho Clinical Diagnostics (OCDX) +8%.Losers: Idera Pharmaceuticals (IDRA) -62%, Praxis Precision Medicines (PRAX) -13%, Acu...
HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end busi...
PainReform ([[PRFX]] +3.6%) entered into securities purchase agreements with certain institutional investors to raise ~$6M through the private placement of 1.3M shares and accompanying warrants to purchase 652,173 shares at a combined purchase price of $4.60/share and accompanying ...
News, Short Squeeze, Breakout and More Instantly...
PainReform Ltd. Company Name:
PRFX Stock Symbol:
NASDAQ Market:
Reaches 50% e nrollment in the s econd p art of its Phase 3 c linical t rial of PRF-110 in b unionectomy Remains on track to announce top-line data i n Q 3 202 4 TEL AVIV, Israel, May 15, 2024 (GLOBE N...
TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer o...
(NewsDirect) PainReform CEO Ilan Hadar joined Steve Darling from Proactive to discuss the company at the forefront of addressing the opioid crisis in the United States, is developing PRF-110, an innovative post-operative pain treatment designed as an alternative to traditional opioids. PR...